In lung adenocarcinoma, we find that the NMD activity can either decrease or increase compared to adjacent normal tissues, suggesting that NMD-inhibition based therapies may result in better effects in some patients than others. The gene discussed is PLA1A; the disease is lung adenocarcinoma.